$0.89
1.89% yesterday
Nasdaq, May 20, 09:48 pm CET
ISIN
US8693671021
Symbol
STRO
Sector
Industry

Sutro Biopharma, Inc. Stock price

$0.90
+0.35 62.90% 1M
-1.77 66.30% 6M
-0.94 51.10% YTD
-3.78 80.78% 1Y
-3.77 80.73% 3Y
-9.19 91.08% 5Y
-14.30 94.08% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.02 2.44%
ISIN
US8693671021
Symbol
STRO
Sector
Industry

Key metrics

Market capitalization $75.99m
Enterprise Value $38.72m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.58
P/S ratio (TTM) P/S ratio 1.14
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -56.88%
Revenue (TTM) Revenue $66.43m
EBIT (operating result TTM) EBIT $-229.33m
Free Cash Flow (TTM) Free Cash Flow $-198.51m
Cash position $248.97m
EPS (TTM) EPS $-2.98
P/E forward negative
P/S forward 1.34
EV/Sales forward 0.68
Short interest 6.38%
Show more

Is Sutro Biopharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Sutro Biopharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Sutro Biopharma, Inc. forecast:

4x Buy
36%
6x Hold
55%
1x Sell
9%

Analyst Opinions

11 Analysts have issued a Sutro Biopharma, Inc. forecast:

Buy
36%
Hold
55%
Sell
9%

Financial data from Sutro Biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
66 66
57% 57%
100%
- Direct Costs 7.36 7.36
4% 4%
11%
59 59
60% 60%
89%
- Selling and Administrative Expenses 34 34
23% 23%
52%
- Research and Development Expense 247 247
25% 25%
371%
-222 -222
131% 131%
-334%
- Depreciation and Amortization 7.36 7.36
4% 4%
11%
EBIT (Operating Income) EBIT -229 -229
121% 121%
-345%
Net Profit -245 -245
113% 113%
-369%

In millions USD.

Don't miss a Thing! We will send you all news about Sutro Biopharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sutro Biopharma, Inc. Stock News

Neutral
GlobeNewsWire
12 days ago
- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization -
Neutral
GlobeNewsWire
19 days ago
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences.
Neutral
GlobeNewsWire
22 days ago
- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - - Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile -
More Sutro Biopharma, Inc. News

Company Profile

Sutro Biopharma Inc. engages in the drug discovery, development, and manufacturing of pharmaceutical products. It focuses on next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jane Chung
Employees 338
Founded 2003
Website www.sutrobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today